IRIS PubliCatt

Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.364
NA - Nord America 1.357
AS - Asia 807
AF - Africa 13
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.550
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.343
CN - Cina 441
DE - Germania 347
IT - Italia 287
SE - Svezia 261
SG - Singapore 198
IE - Irlanda 130
UA - Ucraina 85
ID - Indonesia 79
FR - Francia 51
FI - Finlandia 50
GB - Regno Unito 45
RU - Federazione Russa 44
IN - India 28
TR - Turchia 19
BE - Belgio 15
CA - Canada 13
NL - Olanda 11
IR - Iran 10
JP - Giappone 10
AT - Austria 9
CI - Costa d'Avorio 7
ES - Italia 7
KR - Corea 7
PH - Filippine 7
CH - Svizzera 6
EG - Egitto 6
CZ - Repubblica Ceca 4
LT - Lituania 4
BR - Brasile 3
CL - Cile 3
RO - Romania 3
VN - Vietnam 3
GR - Grecia 2
HK - Hong Kong 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
HU - Ungheria 1
MX - Messico 1
MY - Malesia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.550
Salva come PNG Salva come JPEG
Città #
Chandler 278
Hangzhou 186
Singapore 152
Ashburn 150
Dublin 126
Jakarta 78
Wilmington 61
Beijing 60
San Mateo 60
Rome 56
New York 51
Jacksonville 47
Milan 45
Boston 41
Nanjing 41
Moscow 32
Cattolica 31
Helsinki 30
Princeton 29
Houston 22
Zhengzhou 22
Redwood City 20
Dearborn 18
Lawrence 17
Fairfield 16
Nanchang 16
Washington 16
Ann Arbor 15
Bremen 14
Brussels 13
Izmir 13
Los Angeles 12
Marseille 12
Mountain View 12
Woodbridge 12
Seattle 11
Munich 10
Boardman 9
Nürnberg 9
Andover 8
Busto Arsizio 8
Paris 8
Richardson 8
Abidjan 7
Hebei 7
Leawood 7
Cairo 6
Cambridge 6
Guangzhou 6
Naples 6
Portland 6
Redmond 6
Santa Clara 6
Shanghai 6
Vienna 6
Changsha 5
Falkenstein 5
Kunming 5
London 5
Norwalk 5
Shenyang 5
Tianjin 5
Toronto 5
Turin 5
Amsterdam 4
Antalya 4
Edinburgh 4
Frankfurt am Main 4
Manchester 4
Mumbai 4
New Haven 4
Palermo 4
University Park 4
Asti 3
Augusta 3
Bern 3
Guidonia Montecelio 3
Jeju City 3
Jiaxing 3
Lappeenranta 3
Madrid 3
Martellago 3
Nuremberg 3
Philadelphia 3
Sacramento 3
Sanremo 3
Snodland 3
Winnipeg 3
Ahmedabad 2
Auburn Hills 2
Bari 2
Brescia 2
Brno 2
Cava de' Tirreni 2
Cavite City 2
Chicago 2
Civitavecchia 2
Coimbatore 2
Fisciano 2
Florence 2
Totale 2.100
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 452
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 303
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 141
Sonographic imaging of urinoma 132
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 123
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer 113
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 110
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 97
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 97
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 93
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer 81
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 71
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? 69
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 68
Sonographic imaging of urinoma. 65
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 64
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 59
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 56
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC 55
A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms 55
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 55
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 52
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 50
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer 48
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 48
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 46
Diagnosis of uterine leiomyosarcoma 5 years after magnetic-resonance-guided high-intensity focused ultrasound treatment of fibroid 45
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 44
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 43
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 42
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 40
Newly diagnosed ovarian cancer: Which first-line treatment? 40
Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis 39
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 38
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 38
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 38
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 36
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 36
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 36
PARP Inhibitors Resistance: Mechanisms and Perspectives 34
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases 34
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 34
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 33
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer 33
The role of artificial intelligence in managing multimorbidity and cancer 32
Clear cell carcinoma of the endometrium 32
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma 32
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 31
Recent progress in the use of pharmacotherapy for endometrial cancer 29
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 28
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma 28
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer 28
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 27
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 27
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease 27
Endometrial carcinosarcoma 26
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer 26
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial 25
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 24
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 24
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial 23
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 22
Advanced and recurrent endometrial cancer: State of the art and future perspectives 22
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 22
Dostarlimab: From preclinical investigation to drug approval and future directions 21
Management of stage III and IVa uterine cancer 21
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 21
Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy 20
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 19
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 18
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: A multicenter retrospective study 17
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 17
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 15
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 13
Chemotherapy-free treatments: Are we ready for prime time? 13
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 10
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) 10
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 9
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 1
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 1
Totale 4.047
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.051
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.051
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020272 0 0 0 0 0 0 57 42 55 36 32 50
2020/2021460 29 20 18 37 57 37 66 27 25 59 66 19
2021/2022392 32 21 10 23 24 5 11 60 15 24 61 106
2022/2023896 89 104 60 91 70 114 34 70 136 32 54 42
2023/2024762 19 197 51 48 32 108 71 13 23 35 79 86
2024/2025420 35 40 121 61 97 59 7 0 0 0 0 0
Totale 4.047